Denali Stock Surges 7%, Adding $213 Million, After Hunter Syndrome Drug Sales Guidance

Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.

Share
Denali Stock Surges 7%, Adding $213 Million, After Hunter Syndrome Drug Sales Guidance

Denali Therapeutics shares climbed 6.84% to $20.78 in Wednesday trading as of 9:54 a.m. ET, adding $213 million in market value, the session after the company said its Hunter syndrome drug AVLAYAH brought in $17.8 million in net product revenue last quarter. Management expects AVLAYAH to book $30.0 million to $32.0 million in the fourth quarter.

A voucher sale props up profit

The quarter's bottom line owes to a different deal. Selling a Priority Review Voucher produced a $194.0 million gain, which left Denali with $70.1 million in net income despite a $126.8 million operating loss, according to its quarterly report.

The company held $1.0 billion in cash, cash equivalents and marketable securities as of September 30, it said.

Recovering from a 29% hole

Before the report, Denali's shares sat 29% below their highest close of the past year, set on July 9, as of Tuesday's close. The stock was still up about 18% year to date at that close, against roughly 11% for the S&P 500.

Wednesday's gain put the stock on pace for its biggest one-day rise since June 17, when it rose 7.1%.

What Denali makes and what's next

Denali's TransportVehicle technology is built to ferry enzymes, oligonucleotides and antibodies into the brain. Its programs target rare lysosomal storage diseases such as Hunter syndrome, and common neurodegenerative diseases such as Alzheimer's and Parkinson's. Its income comes from collaborations with Biogen, Takeda and Sanofi.

The company plans to file a biologics license application, its approval request to the FDA, for its Sanfilippo syndrome program in 2027.

Fourth-quarter AVLAYAH sales will be the first test of the $30.0 million to $32.0 million guidance.

Sources

More on Denali Therapeutics

All Denali Therapeutics (DNLI) coverage →